No difference observed in the risk of malignancy in patients exposed to omalizumab compared with controls

R. Buhl, C. Fernandez Vidaurre, M. Blogg, J. Zhu, M. D. Eisner, J. Canvin, W. Busse (Mainz, Germany; East Hanover, South San Francisco, Madison, United States Of America; Horsham, United Kingdom)

Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Session: Airways disease comorbidities and general aspects
Session type: Thematic Poster Session
Number: 4004

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Buhl, C. Fernandez Vidaurre, M. Blogg, J. Zhu, M. D. Eisner, J. Canvin, W. Busse (Mainz, Germany; East Hanover, South San Francisco, Madison, United States Of America; Horsham, United Kingdom). No difference observed in the risk of malignancy in patients exposed to omalizumab compared with controls. Eur Respir J 2011; 38: Suppl. 55, 4004

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Patients at risk for COPD compared to patients diagnosed with COPD
Source: Annual Congress 2009 - Epidemiology of COPD
Year: 2009


COPD incidence in OSAS patients (overlap syndrome) and differences between groups
Source: Eur Respir J 2005; 26: Suppl. 49, 566s
Year: 2005

Retrospective review of studies shows that patients receiving salmeterol plus ICS have fewer serious asthma exacerbations vs patients on ICS alone, regardless of ethnic origin
Source: Eur Respir J 2005; 26: Suppl. 49, 429s
Year: 2005

SARS-Cov-2 infection in asthma patients treated with biologics
Source: Virtual Congress 2021 – Exacerbations of chronic respiratory diseases, including SARS-CoV-2
Year: 2021



Significant percentage of asthma patients failed to achieve control in the first year after initiating medium or high dose ICS/LABA
Source: International Congress 2017 – Primary care management of asthma and self-management of respiratory disease
Year: 2017


Relationship between asthma control test (ACT) and clinical, functional and inflammatory markers in treated and non treated asthmatics
Source: Annual Congress 2008 - Inflammatory biomarkers
Year: 2008

Treatment complication rates in continued smokers vs quitters after a diagnosis of lung cancer: a cohort study
Source: Virtual Congress 2020 – From tobacco and vaping health effects to tobacco cessation
Year: 2020




The lung deposition of tiotropium in COPD patients is comparable to that in healthy subjects and independent of the stage of COPD disease
Source: Eur Respir J 2003; 22: Suppl. 45, 51s
Year: 2003

Montelukast induces better control of symptoms and management of lung function, and decreased inflammation in women compared with men.
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019

A prospective study to detect ICIs’ associated Myocarditis, among patients treated for lung cancer
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021

Comparison of demographics in quitters compared to continued smokers in patients with lung cancer
Source: International Congress 2017 – Noteworthy lung cancer patient reports: reported outcome measures, smoking cessation, weight and sleep disorders
Year: 2017

Differences in migrating neutrophils from patients with COPD compared with healthy smokers and non smokers and patients with alpha 1 antitrypsin deficiency
Source: Annual Congress 2010 - Novel mechanisms in COPD
Year: 2010

The influence of smoking on the treatment response in patients with asthma
Source: Annual Congress 2007 - PG15 - Difficult-to-treat asthma: dealing with smoker patients
Year: 2007

The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019




Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021


Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study)
Source: Eur Respir J , 49 (3) 1501885; DOI: 10.1183/13993003.01885-2015
Year: 2017



Lymphopenia is linked to an increased incidence of cancer in smokers without COPD
Source: International Congress 2019 – Airway diseases and blood cells
Year: 2019

Exacerbation rates of COPD in hospital patients, population based cases and controls
Source: Annual Congress 2009 - Exacerbations and characteristics of COPD
Year: 2009


Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide
Source: Eur Respir J 2005; 26: Suppl. 49, 255s
Year: 2005

The risk factors in asthma patients for COVID19 infection
Source: Virtual Congress 2021 – COVID-19 and obstructive diseases: risk factors, management and long-term effects
Year: 2021